Citations

Clear

6 citation(s) found for "Marsolo, Keith".

Computable phenotypes for research using real-world data: experiences from the NIH pragmatic trials collaboratory
Conte, Marisa , Fiol, Guilherme Del , Campbell, James R, Marsolo, Keith, Ezenwa, Miriam O. , Darby, Juanita E. , Matthie, Nadine , Ho, P Michael, Pressman, Alice, Justice, Morgan, Fist, Alex , Staman, Karen, Wu, Hulin, Conte, Marisa L , Del Fiol, Guilherme , Stephens, Kari A , Darby, Juanita E , Reynolds Geary, Carol , Faurot, Keturah R , Schlaeger, Judith M. , Campbell, James R., Cheville, Andrea , Stephens, Kari A. , Boyd, Andrew D. , Ho, P. Michael , Pressman, Alice , Geary, Carol , Faurot, Keturah R. , Staman, Karen L. , Wu, Hulin, Richesson, Rachel

Mayo Clinic

JAMIA Open | July 29, 2026 | Volume: 9 | Issue: 4 | Pages: No page available

10.1093/jamiaopen/ooag158 | PMID 42559354 Get It

Abstract Objectives Embedded pragmatic clinical trials (ePCTs) are conducted as part of routine clinical care and therefore use data collected from real-world data sources, such as electronic health record systems and administrative claims. A common approach for using these types of data across all phases of trial conduct is to create a computable phenotype (an explicitly defined data query data, including specified data types, data codes, and logical parameters) to capture patients with a clinical condition, exposure, symptom, characteristic, treatment, or outcome of interest. Materials and Methods The Electronic Health Record (EHR) Core Working Group of the NIH Pragmatic Trials Collaboratory captured the experiences of investigators in developing, adapting, and applying computable phenotype definitions in their studies. Results Four case studies describe different approaches to developing and using computable phenotypes in pragmatic trials. Discussion We recommend: (1) developing computable phenotypes as part of a team with multiple areas of expertise; (2) appropriate validation; (3) dissemination of salient details regarding phenotype creation; and (4) capturing and reporting any modifications made to phenotypes during the conduct of the trial. Conclusion A range of issues and decisions influence how computable phenotypes are developed and used in pragmatic clinical trials. Multidisciplinary teams that understand the context of the data, including the reason the data are collected and potential sources of bias, are best suited for the development and validation of phenotypes for ePCTs.
Investigating the Use of the Fast Health Care Interoperability Resources (FHIR) Standard to Support Data Activities Across the PCORnet® Infrastructure: Lessons Learned From the FHIR Pilots of the Coordinating Center for PCORnet®
Marsolo, Keith S, Louzao, Darcy, Hart, Kim Ward, Shrader, Peter, Hawley, Jeffrey , Delacqua, Francesco, Thomas, E D, Wick, Joseph, Chamberlain, Alanna M., JONES, WILLIAM S., Rothman, Russell L., Harris, Paul A., Cheng, Alex C., Marsolo, Keith , Hart, Kim, Thomas, Ellis, Wick, Joseph J., Chamberlain, Alanna M. , Rothman, Russell L. , Harris, Paul A. , Cheng, Alex

Mayo Clinic

Medical Care | January 8, 2026 | Volume: 64 | Issue: 3S | Pages: S233-S241

10.1097/mlr.0000000000002236 | PMID 41504752 Get It

Background: Institutions that participate in PCORnet ® transform their local electronic health record (EHR) data into the PCORnet ® Common Data Model (CDM), which is then used to generate data extracts for PCORnet ® Studies. PCORnet ® Studies can also include institutions that do not participate in PCORnet, and for these organizations, the cost of instantiating a PCORnet ® CDM can be prohibitive. Fast Health care Interoperability Resources (FHIR) provides an alternative method of obtaining EHR data. Objective: To determine whether data obtained through FHIR might be a viable study solution for those sites that do not participate in PCORnet. ® This mixed-methods project had 2 objectives: (1) survey sites participating in PCORnet on the availability of FHIR (FHIR survey); (2) compare the coverage of a FHIR-based data extract using REDCap with one from the PCORnet ® CDM across 3 sites (FHIR extract). Methods: (1) FHIR survey: A series of questions were asked about the use of FHIR in a production capacity. (2) FHIR extract: REDCap FHIR and PCORnet ® CDM extracts were created based on study variables from 2 prior PCORnet ® Studies. Data were extracted for 40 patients and concordance measures were computed between the 2 sources. Results: (1) FHIR survey: Of responding organizations, 73% (n=49) reported that FHIR was deployed in a production capacity. (2) FHIR extract: Results were highly variable. Cohen kappa ranged from 0.01 to 0.76 for certain diagnoses, 0.24 to 0.84 for laboratory results, and 0.1 to 0.87 for medications. Conclusions: Despite differences in data, certain studies may be well-suited for FHIR-based extracts.
Using Electronic Health Records to Classify Cancer Site and Metastasis
Ruddy, Kathryn J. , Pachman, Deirdre R. , Grzegorczyk, Veronica , Rahman, Parvez, Tobin, Kyle A., Chlan, Linda L., Marsolo, Keith , Lam, Veronica , Rahman, Parvez A, Kroenke, Kurt , Herrin, Jeph , Tobin, Kyle A., Griffin, Joan M. , Austin, Jessica D. , Ridgeway, Jennifer L. , Mitchell, Sandra A , Cheville, Andrea

Mayo Clinic

Applied Clinical Informatics | June 19, 2025 | Volume: 16 | Issue: 03 | Pages: 556-568

10.1055/a-2544-3117 | PMID 40533095 Get It

AbstractThe Enhanced EHR-facilitated Cancer Symptom Control (E2C2) Trial is a pragmatic trial testing a collaborative care approach for managing common cancer symptoms. There were challenges in identifying cancer site and metastatic status.This study compares three different approaches to determine cancer site and six strategies for identifying the presence of metastasis using EHR and cancer registry data.The E2C2 cohort included 50,559 patients seen in the medical oncology clinics of a large health system. SPPADE symptoms were assessed with 0 to 10 numeric rating scales (NRS). A multistep process was used to develop three approaches for representing cancer site: the single most prevalent International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10) code, the two most prevalent codes, and any diagnostic code. Six approaches for identifying metastatic disease were compared: ICD-10 codes, natural language processing (NLP), cancer registry, medications typically prescribed for incurable disease, treatment plan, and evaluation for phase 1 trials.The approach counting the two most prevalent ICD-10 cancer site diagnoses per patient detected a median of 92% of the cases identified by counting all cancer site diagnoses, whereas the approach counting only the single most prevalent cancer site diagnosis identified a median of 65%. However, agreement among the three approaches was very good (kappa > 0.80) for most cancer sites. ICD and NLP methods could be applied to the entire cohort and had the highest agreement (kappa = 0.53) for identifying metastasis. Cancer registry data was available for less than half of the patients.Identification of cancer site and metastatic disease using EHR data was feasible in this large and diverse cohort of patients with common cancer symptoms. The methods were pragmatic and may be acceptable for covariates, but likely require refinement for key dependent and independent variables.
Potential bias and lack of generalizability in electronic health record data: reflections on health equity from the National Institutes of Health Pragmatic Trials Collaboratory
Boyd, Andrew D. , Lawrence, Katharine , Patil, Crystal L. , Ezenwa, Miriam O. , O’Brien, Emily C. , Paek, Hyung , Adeyemi, Oluwaseun , Cuthel, Allison M. , Darby, Juanita E. , Zigler, Christina K. , Faurot, Keturah R, Staman, Karen L. , Dailey, Dana L. , Fiol, Guilherme Del , Knisely, Mitchell R. , Marsolo, Keith , Richesson, Rachel , Faurot, Keturah R. , Lawrence, Katharine , O'Brien, Emily , Cuthel, Allison M , Darby, Juanita E , Del Fiol, Guilherme , Richesson, Rachel L , Boyd, Andrew D , Faurot, Keturah R , Gonzalez-Guarda, Rosa Maria , Braciszewski, Jordan M. , Ho, P. Michael , Leigh, Jonathan W. , Cheville, Andrea , Grudzen, Corita R. , Schlaeger, Judith M.

Mayo Clinic

Journal of the American Medical Informatics Association | June 15, 2023 | Volume: 30 | Issue: 9 | Pages: 1561-1566

10.1093/jamia/ocad115 | PMID 37364017 Get It

Abstract Embedded pragmatic clinical trials (ePCTs) play a vital role in addressing current population health problems, and their use of electronic health record (EHR) systems promises efficiencies that will increase the speed and volume of relevant and generalizable research. However, as the number of ePCTs using EHR-derived data grows, so does the risk that research will become more vulnerable to biases due to differences in data capture and access to care for different subsets of the population, thereby propagating inequities in health and the healthcare system. We identify 3 challenges—incomplete and variable capture of data on social determinants of health, lack of representation of vulnerable populations that do not access or receive treatment, and data loss due to variable use of technology—that exacerbate bias when working with EHR data and offer recommendations and examples of ways to actively mitigate bias.
Empowering genomic medicine by establishing critical sequencing result data flows: the eMERGE example
Aronson, Samuel , Babb, Lawrence , Ames, Darren C., Gibbs, Richard A. , Connelly, John, Marsolo, Keith , Hartzler, Andrea L. , Liang, Wayne H. , Ralston, James D. , Devine, Emily Beth , Murphy, Shawn N. , Freimuth, Robert R. , Rasmussen, Luke V. , Peterson, Josh F. , Robinson, Jamie R. , Wiley, Ken, Taylor, Casey Overby , Group, eMERGE Network EHRI Working, Caraballo, Pedro J. , Babb, Lawrence , Rasmussen, Luke V , Freimuth, Robert R , Venner, Eric , Weng, Chunhua , Williams, Marc S , Chute, Christopher G. , Kullo, Iftikhar J. , Wehbe, Firas , Group, eMERGE Network EHRI Working, Peterson, Josh F

Mayo Clinic

Journal of the American Medical Informatics Association | April 19, 2018 | Volume: 25 | Issue: 10 | Pages: 1375-1381

10.1093/jamia/ocy051 | PMID 29860405 Get It

AbstractThe eMERGE Network is establishing methods for electronic transmittal of patient genetic test results from laboratories to healthcare providers across organizational boundaries. We surveyed the capabilities and needs of different network participants, established a common transfer format, and implemented transfer mechanisms based on this format. The interfaces we created are examples of the connectivity that must be instantiated before electronic genetic and genomic clinical decision support can be effectively built at the point of care. This work serves as a case example for both standards bodies and other organizations working to build the infrastructure required to provide better electronic clinical decision support for clinicians.
Effectiveness of Anti-TNFα for Crohn Disease: Research in a Pediatric Learning Health System
Crandall, Wallace, Joffe, Marshall M., Colletti, Richard B. , Adler, Jeremy, Baron, Howard, Berman, James , Rosario, J. Fernando del , Grossman, Andrew B., Israel, Esther J. , Kim, Sandra C. , Lightdale, Jenifer R. , Margolis, Peter A. , Marsolo, Keith , Mehta, Devendra I. , Milov, David E., Patel, Ashish , Tung, Jeanne , Forrest, Christopher B. , Bailey, L. Charles , Zhang, Peixin , Adler, Jeremy, Hoffenberg, Edward J. , Kappelman, Michael D. , Adler, J

Mayo Clinic

Pediatrics | June 17, 2014 | Volume: 134 | Issue: 1 | Pages: 37-44

10.1542/peds.2013-4103 | PMID 24935993 Get It

OBJECTIVES: ImproveCareNow (ICN) is the largest pediatric learning health system in the nation and started as a quality improvement collaborative. To test the feasibility and validity of using ICN data for clinical research, we evaluated the effectiveness of anti-tumor necrosis factor-α (anti-TNFα) agents in the management of pediatric Crohn disease (CD). METHODS: Data were collected in 35 pediatric gastroenterology practices (April 2007 to March 2012) and analyzed as a sequence of nonrandomized trials. Patients who had moderate to severe CD were classified as initiators or non-initiators of anti-TNFα therapy. Among 4130 patients who had pediatric CD, 603 were new users and 1211 were receiving anti-TNFα therapy on entry into ICN. RESULTS: During a 26-week follow-up period, rate ratios obtained from Cox proportional hazards models, adjusting for patient and disease characteristics and concurrent medications, were 1.53 (95% confidence interval [CI], 1.20–1.96) for clinical remission and 1.74 (95% CI, 1.33–2.29) for corticosteroid-free remission. The rate ratio for corticosteroid-free remission was comparable to the estimate produced by the adult SONIC study, which was a randomized controlled trial on the efficacy of anti-TNFα therapy. The number needed to treat was 5.2 (95% CI, 3.4–11.1) for clinical remission and 5.0 (95% CI, 3.4–10.0) for corticosteroid-free remission. CONCLUSIONS: In routine pediatric gastroenterology practice settings, anti-TNFα therapy was effective at achieving clinical and corticosteroid-free remission for patients who had Crohn disease. Using data from the ICN learning health system for the purpose of observational research is feasible and produces valuable new knowledge.